- Raised $800k funding round, Nov 2016
About
CorAlert is developing a noninvasive device for the early detection and monitoring of heart failure in real time. Suitable for both inpatient and outpatient environments, the device accurately estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from measurements of pressure at the brachial artery and timing measurements based on heartbeat sounds. The CorAlert device provides a comprehensive hemodynamic picture that includes the rate of pressure increase in the aorta during ejection (dP/dt) and an index correlated to systemic vascular resistance (SVR). The comprehensive hemodynamic profile supplied by the device enables the physician to accurately determine each patients precise condition and type of dysfunction. The companys solution was validated in 10 patients in a clinical trial conducted at Ziv Medical Center in Israel using CorAlerts alpha model. CorAlert has completed production of its beta model, which has commenced a clinical trial in Israel.
Funding history · 1 round · $800K total
Q&A
- What is CorAlert's primary focus?
- CorAlert is developing a noninvasive device for the early detection and real-time monitoring of heart failure.
- What is the current status of CorAlert?
- CorAlert is currently inactive and ceased to operate in March 2023.
- What is CorAlert's total funding to date?
- CorAlert has raised a total of $800,000.
- When was CorAlert's last funding round and who were the investors?
- CorAlert's last funding round was in November 2016, with investments from The Trendlines Group and Israel Innovation Authority.
- What is the core technology behind CorAlert's device?
- The CorAlert device estimates left ventricular end-diastolic pressure (LVEDP) by analyzing central aortic pressure derived from brachial artery measurements and heartbeat timing.
- Has CorAlert's solution undergone clinical validation?
- Yes, CorAlert's alpha model was validated in a clinical trial with 10 patients at Ziv Medical Center in Israel. Its beta model has also commenced a clinical trial in Israel.
- What type of customers does CorAlert target?
- CorAlert targets customers in Healthcare & Life Sciences, specifically within Healthcare Providers.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/35430259 |
Identifiers & details
| Founded | 2012-12 |
|---|---|
| Employees (exact) | 4 |
| Status reason | Non Active, Mar 2023 ceased to operate |